Health and Healthcare

Celgene : CELG

All CELG Articles

433 Articles

Jon C. Ogg | May 23, 2015 at 9:30 AM EDT

The Most Loved Biotechs of Big Hedge Funds

There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend…

Chris Lange | May 12, 2015 at 8:05 AM EDT

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks,…

Lee Jackson | May 6, 2015 at 10:00 AM EDT

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the…

Chris Lange | Apr 30, 2015 at 8:50 AM EDT

Is Celgene Stumped on Its Portfolio?

Celgene released mixed first-quarter results before the markets opened Thursday and shares were down in early trading.

Chris Lange | Apr 29, 2015 at 3:05 PM EDT

What to Expect From Celgene Earnings

ThinkstockCelgene Corp. (NASDAQ: CELG) is scheduled to release its first-quarter financial results before the markets open Thursday. Thomson Reuters has…

Chris Lange | Apr 27, 2015 at 8:30 AM EDT

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech…

Jon C. Ogg | Apr 13, 2015 at 2:00 PM EDT

Can a Small New Stem Cell Pact Move the Needle for Celgene?

Celgene is one of the world's top biotech stocks now, and its market cap is nearly $100 billion. The company…

Chris Lange | Apr 13, 2015 at 8:35 AM EDT

Short Sellers Increase Their Bets Against Biotech Stocks

The March 31 short interest data have been compared with the March 13 figures, and for most of the selected…

Chris Lange | Mar 25, 2015 at 9:15 AM EDT

Major Biotech Is So-So for Short Sellers

The March 13 short interest data in top biotechs have been compared with the end of February figures, and across…

Chris Lange | Mar 18, 2015 at 2:10 PM EDT

How the Weaker Euro Is Impacting Biotech Earnings

Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.

Chris Lange | Mar 11, 2015 at 9:15 AM EDT

Short Sellers Get More Aggressive on Big Biotech

24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with…

Lee Jackson | Mar 4, 2015 at 8:35 AM EST

The 5 Most Loved Biotech Stocks of Portfolio Managers

A big part of the Nasdaq is biotech, and a new report from Cowen details the stocks that big money…

Chris Lange | Feb 26, 2015 at 9:25 AM EST

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech…

Chris Lange | Feb 18, 2015 at 3:31 PM EST

Is Revlimid Becoming a Catch-All Cancer Drug?

Celgene has announced that the FDA expanded the existing indication for Revlimid in conjunction with dexamethasone.

Lee Jackson | Feb 18, 2015 at 8:25 AM EST

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid…

1 … 16 17 18 19 20 … 29

Celgene : CELG

All CELG Articles

The Most Loved Biotechs of Big Hedge Funds

Short Sellers Start to Get Nervous on Biotech

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Is Celgene Stumped on Its Portfolio?

What to Expect From Celgene Earnings

Short Sellers Become More Wary of Big Biotech

Can a Small New Stem Cell Pact Move the Needle for Celgene?

Short Sellers Increase Their Bets Against Biotech Stocks

Major Biotech Is So-So for Short Sellers

How the Weaker Euro Is Impacting Biotech Earnings

Short Sellers Get More Aggressive on Big Biotech

The 5 Most Loved Biotech Stocks of Portfolio Managers

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

Is Revlimid Becoming a Catch-All Cancer Drug?

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Celgene : CELG

All CELG Articles

The Most Loved Biotechs of Big Hedge Funds

Short Sellers Start to Get Nervous on Biotech

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Is Celgene Stumped on Its Portfolio?

What to Expect From Celgene Earnings

Short Sellers Become More Wary of Big Biotech

Can a Small New Stem Cell Pact Move the Needle for Celgene?

Short Sellers Increase Their Bets Against Biotech Stocks

Major Biotech Is So-So for Short Sellers

How the Weaker Euro Is Impacting Biotech Earnings

Short Sellers Get More Aggressive on Big Biotech

The 5 Most Loved Biotech Stocks of Portfolio Managers

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

Is Revlimid Becoming a Catch-All Cancer Drug?

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%